CBC Group, Asia’s largest healthcare-dedicated investment firm, is committed to creating value and integrating global resources. Partnering with the world’s top entrepreneurs and scientists, its unique “investor-operator” approach has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide. Founded in 2014, CBC has a leading team of investment, industry and portfolio management professionals headquartered in Singapore with offices in Shanghai, Beijing, Hong Kong and New York, and presences in Boston, San Diego, San Francisco, and Tokyo. CBC focuses on platform-building, buyout, credit and growth-focused opportunities across multiple core areas within the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services.
Location: Singapore
Employees: 51-200
Founded date: 2014
Investment Type: Venture Capital
Portfolio 16
| Date | Name | Website | Total Raised | Location |
| - | Fujian Her... | berrygenomics.com | - | China, Bei... |
| - | Anrei Medi... | anreimedical.medincn.com | - | - |
| - | Lu Daopei ... | ludaopei.com | - | - |
| - | 济川药业... | jumpcan.com | - | China, Jia... |
| - | I-Mab Biop... | i-mabbiopharma.com | $678M | United Sta... |
| - | fitomedical.net | - | - | |
| - | cq-pharm.com | - | - | |
| - | 南京江北医院... | njjbrmyy.net | - | - |
| - | Clarus The... | clarustherapeutics.com | $30M | Canada, On... |
| - | CMAB Bioph... | cmabbio.com | $72M | - |
Show more
News 34
| Date | Title | Description |
| 25.12.2021 | Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board | Sep.30, 2021 RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA) platform company in Singapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and ther... |
| 25.12.2021 | CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan | Oct.12, 2021 Agreement to accelerate the development and commercialization of odevixibat in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia Bylvay TM (odevixibat) approved in U.S., EU and UK with global presc... |
| 16.06.2021 | Deal focus: NiKang pursues hard-to-drug targets | Tim Burroughs 01 June 2021 Healthcare investor CBC Group is best known for backing start-ups that license nascent treatments from the US and develop drugs for the China market. Everest Medicines, a biotech player incubated by CBC, leverag... |
| - | AbbVie puts $2B on the table for I-Mab cancer collab as biotech nabs $418M raise | It’s a good day for Shanghai-based I-Mab, which has penned a $2 billion upfront-biobucks R&D deal with AbbVie while also nabbing $418 million from investors. First up, the AbbVie deal, which is made up of a $180 million upfront payment... |
| - | I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board | SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today ... |
| - | AffaMed Therapeutics Receives NMPA Approval to Initiate Phase III Clinical Trial in China with Herceptin® (Trastuzumab) Biosimilar Candidate AMT901 | SHANGHAI, China, Dec. 10, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a biopharmaceutical company founded and funded by CBC Group, a healthcare private equity rm focused on the development and late-stage investment opportunities, today a... |
| - | I-Mab Added to Nasdaq Biotechnology Index | NEWS PROVIDED BY I-Mab Dec 14, 2020, 08:00 ET SHARE THIS ARTICLE SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the... |
| - | I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium | NEWS PROVIDED BY I-Mab Sep 04, 2020, 07:01 ET SHARE THIS ARTICLE SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to... |
| - | CMAB Biopharma Announces Dr. Wang Yongzhong as CEO to Strengthen Leadership and Continue Business Expansion | SUZHOU, China and NEW YORK, May 20, 2019 /PRNewswire/ -- CMAB Biopharma Limited. (CMAB), a strict "pure-play" contract development and manufacturing organization (CDMO) focusing solely on services from sequence to commercial manuf... |
| - | Nuance Pharma Announces Strategic Licensing Deal with Antibe Therapeutics in China | NEWS PROVIDED BY Nuance Pharma Feb 09, 2021, 07:00 ET SHARE THIS ARTICLE TORONTO and SHANGHAI, Feb. 9, 2021 /PRNewswire/ -- Antibe Therapeutics Inc. (TSX: ATE,OTCQB: ATBPF) today announced that it has licensed otenaproxesul to Nuance ... |
Show more
Mentions in press and media 39
| Date | Title | Description |
| 20.05.2026 | GHO Capital and CBC Group to Create World's Largest Dedicated Healthcare Investment Firm | Two of the world's leading specialist healthcare investors with over $21 billion AUM are joining forces to create the largest dedicated healthcare investment manager globally Together, the group will have presence across North America, Euro... |
| 22.04.2026 | Dawn Medical Technologies Acquires Controlling Interest in Pinnacle Health in Vietnam | Strategic entry into high-growth Vietnam market Combines Dawn's product sourcing capabilities with Pinnacle Health's established local presence and market expertise Advances Dawn's mission to expand access to high-quality, affordable medica... |
| 13.01.2025 | CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for Mirxes to Advance Global Expansion | - R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech company's innovation and commercialization of cancer e... |
| 12.12.2024 | CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion | Non-dilutive growth financing of up to US$50 million, with a synthetic royalty feature, and availability linked to achievement of certain sales milestones Proceeds from the financing will fund Human Investments Ltd.'s expansion of Motiva® d... |
| 30.11.2024 | The Surge of Private Equity in India’s Financial Services: A New Era of Investment | India's financial services sector is a vibrant landscape, teeming with opportunity. Private equity (PE) investors are flocking to this market, eager to carve out their share of the pie. The recent surge in investments is not just a trend; i... |
| 30.11.2024 | CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China | CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million. New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. Strate... |
| 04.07.2024 | CBC Group's Hasten Biopharmaceutical Expands Portfolio with Celltrion Legacy Products | CBC Group's Hasten Biopharmaceutical, backed by CBC's unique "investor-operator" model, acquires 14 branded products from Celltrion, marking a strategic move towards international expansion and growth in the healthcare sector. In ... |
| 01.07.2024 | CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products | The deal leverages CBC's hands-on "investor-operator" approach to accelerate portfolio companies' asset acquisition and strategic international expansion SINGAPORE, July 1, 2024 /PRNewswire/ -- CBC Group ("CBC"), Asia's ... |
| 30.06.2024 | CBC-Backed Hasten Biopharmaceutical Announces Acquisition of 14 Celltrion Legacy Products | The deal leverages CBC's hands-on "investor-operator" approach to accelerate portfolio companies' asset acquisition and strategic international expansion SINGAPORE, June 30, 2024 /PRNewswire/ -- CBC Group ("CBC"), Asia's... |
| 28.06.2024 | Hasten Announces Acquisition of 14 Celltrion Legacy Products, Accelerating its Business Expansion in the Pan-Asia Area | SHANGHAI, June 28, 2024 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. (referred to as "Hasten") announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions f... |
Show more